The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Amoclav 125mg/31.25mg per 5ml Powder for Oral Suspension

Rowex LtdPA0711/162/001

Main Information

Trade NameAmoclav 125mg/31.25mg per 5ml Powder for Oral Suspension
Active Substancespotassium clavulanate
Amoxicillin trihydrate
Dosage FormPowder for oral suspension
Licence HolderRowex Ltd
Licence NumberPA0711/162/001

Group Information

ATC CodeJ01CR Combinations of penicillins, incl. beta-lactamase inhibitors
J01CR02 amoxicillin and enzyme inhibitor


License statusAuthorised
Licence Issued21/03/2003
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version

Generics Information

Interchangeable List CodeIC0037-071-034
Interchangeable List DocumentPDF of Interchangeable List
« Back